natgillin/translations-raw huggingface dataset:
The present invention can also be used for multiple twisted rudders, wherein then at least one flow body is respectively to be provided in each transition area between the single sections of the front leading edge and/or the rear trailing edge. Preferably, the shape of the flow body is configured in such a manner that the flow body closes the rudder profile fluidically in the area of the offset surfaces. 
što tijelo oko kojega prolazi strujanje (41) završava uglavnom tako da je izravnano najmanje s jednim od predjela čeonog ruba (11, 21) i/ili s jednim od predjela stražnjeg ruba (304, 30b), što je tijelo oko kojega prolazi strujanje (41) postavljeno na razmaku od glavčine propelera brodskog propelera, i što kormilo nema Costa - odebljanje.
The binding molecule of claim 1, wherein the pharmacologically active agent comprises an agent that is selected from the group consisting of a neuroactive peptide, a cytokine, and a variable region of an antibody that binds to a target in the central nervous system. 
Vezivna molekula u skladu s patentnim zahtjevom 1, naznačena time što se farmaceutski aktivno sredstvo bira iz skupine koju čine neuroaktivni peptid, mali kemijski entitet, te varijabilno područje protutijela koje se veže na metu u središnjem živčanom sustavu.
demodulating the broadcast signal by performing a guard interval removal and a FFT on the broadcast signal; 
demoduliranja emitiranog signala uklanjanjem intervala čuvara i FFT na emitiranom signalu;
According to another preferred aspect, each of said groups of single-use packages is adapted according to liquid production parameters including type of beverage, quantity of beverage, amount of foam in beverage to be produced in respective single-use packages. Another object of the present invention is to provide a process for the preparation of liquid products in a system including such single-portion packages. 
Sustav (10) sukladno bilo kojem od prethodnih zahtjeva 9 ili 10, naznačen time što je svaka od grupa pakiranja za jednu uporabu (1, 1*) prilagođena sukladno parametrima proizvodnje tekućine uključujući vrstu pića, količinu pića, količinu pjene u piću koje će se proizvoditi u odnosu na pakiranja za jednu uporabu (1, 17).
This agglomeration method is certainly a suitable process for the production of agglomerates from liquid feedstocks, i.e. 
Ta metoda aglomeracije je svakako prikladna za dobivanje aglomerata od tekućeg polaznog materijala, tj.
The device is characterized in that the surface of said permanently magnetized body carries indicia in the form of irregularities of the surface, particularly deepenings or heightenings. 
Značajka je uređaja to da površina navedenog permanentno magnetiziranog tijela sadržava oznaku u obliku nepravilnosti na površini, posebice se to odnosi na udubljenja ili ispupčenja.
The method according to claim 1, wherein the block is made of a ceramic material. 
Postupak sukladno patentnom zahtjevu 1, naznačen time, da je blok (1) načinjen od keramičkog materijala.
iv-1) a solid oral dosage form comprising about 100 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 205 ng/ml +/- 47 ng/ml following oral administration of said dosage form, in a patient not treated with vildagliptin before said administration and wherein said patient is under fasted conditions, and/or 
Vildagliptina od 205 ng/mL +/- 47 ng/mL nakon oralne primjene navedenog dozirnog oblika pacijentu koji nije bio tretiran vildagliptinom prije navedene primjene i pri čemu je pacijent pod uvjetima posta, i/ili kruti oralni dozirni oblik koji sadrži oko 100 mg vildagliptin slobodne baze ili odgovarajuću količinu njegove farmaceutski prihvatljive soli, te podlogu, pri čemu navedeni dozirni oblik pruža srednju vrijednost Cmax.
a method of modifying cytokine secretion in a subject who is sensitive to gluten, optionally wherein interleukin-2 (IL-2), interferon gamma (IFNY) and/or tumour necrosis factor alpha (TNFa) secretion is reduced and/or interleukin-10 (IL-10) secretion is increased. 
Pripravak, cjepivo i/ili stanica koja ispoljava antigen prema zahtjevu 10, za uporabu u postupku kao što je definirano u zahtjevu 10, naznačen time da je u postupku smanjeno izlučivanje interleukina-2 (IL-2), interferona gama (IFNY) i/ili čimbenika tumorske nekroze alfa (TNFa) i/ili je povećano izlučivanje interleukina-10 (IL-10).
The method of claim 1, wherein the camera comprises at least one lens. 
Postupak prema zahtjevu 18, naznačen time da kamera sadrži barem jednu leću.
Most preferable herbicide tolerant or herbicide resistant crops according to the invention is oilseed rape, canola (brassica napus). 
Najpoželjnije kulture koje podnose herbicid ili koje su otporne na herbicid prema izumu su uljana repica, kanola (Brassica napus).
A kit of the invention may comprise: 
Datum objave europskog patenta:
The tablet of claim 1, wherein the dissolving tablet matrix has instant release characteristics. 
Tableta prema zahtjevu 1, naznačena time, da rastapajuća tabletna matrica ima svojstva trenutačnog oslobađanja.
Millipore® YM10 and YM1 filters may be used to determine contents of components with a molecular weight in excess of 10 kDa and 1 kDa respectively. 
Millipore* YM10 i YMI filtri se mogu upotrijebiti za određivanje sadržaja komponenata s molekulskom masom većom od 10 kDa i 1 kDa, pojedinačno.
The compound for use according to claim 6, wherein at least one internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage, wherein optionally each internucleoside linkage of the modified oligonucleotide is a modified internucleoside linkage. 
Spoj za upotrebu prema zahtjevu 5, pri čemu bar jedna internukleozidna veza modificiranog oligonukleotida je modificirana internukleozidna veza, pri čemu opcionalno svaka internukleozidna veza modificiranog oligonukleotida je modificirana internukleozidna veza.
The rodent of claim 1, wherein the rodent is a mouse. 
Glodavac iz zahtjeva 1., pri čemu je glodavac miš.
The epoxidation reaction is conveniently carried out in an alcohol solvent such as methanol, typically at around room temperature. 
Reakcija epoksidacije se uobičajeno provodi u alkoholnom otapalu poput metanola, obično na temperaturi oko sobne temperature.
Figures 1 to 4 show the data measured during the inoculum preparation process (n=10). 
Slike 1 do 4 pokazuju podatke mjerene tijekom procesa priprave inokuluma (n=10).
Addition of 4-iodo-aniline followed by palladium catalyzed coupling with the appropriate boronic acid or stannane gives the desired compound. 
Dodavanje 4-jod- 5 > anilina nakon čega slijedi paladijem katalizirano spajanje s odgovarajućom bornom kiselinom ili stananom daje željeni spoj.
The process according to claim 11, wherein the step of treating the multimer with acid and with enzyme is performed without separation of the reaction products prior to enzyme treatment. 
Postupak prema zahtjevu 11, gdje se korak obrade multimera kiselinom i enzimom provodi bez odvajanja produkata reakcije prije obrade enzimom.
drying the cellulose/plastic waste mixture by treatment with a medium with a temperature in the range of 50 to 150 °C, wherein the water content is reduced to 15 weight% or less; 
(a) sušenje celulozno/plastične mješavine otpada tretiranjem s medijem pri temperaturi u rasponu od 50 do 150 "C, pri čemu je sadržaj vode reduciran na 15 težinskih% ili manje;
• the dose of haemagglutinin per viral strain per single intranasal or inhalational administration is lower or equal to 30 ug, characterized in that no separate adjuvant and/or immune stimulator is added to the composition. 
* > doza haemaglutinina po virusnom soju po jednom intranazalnom ili inhalacijskom davanju je manja ili jednaka 30 ug, naznačena time da nema odvojenog dodavanja adjuvanta i/ili imunološkog stimulatora u pripravak.
The use of a compound as defined in any one of 1 to 53 for the manufacture of a medicament for the prophylaxis or treatment of a disease state or condition mediated by protein kinase A. 
(b) proizvodnju lijeka za prevenciju ili liječenje bolesti ili stanja posredovanog protein kinazom A; ili
Knee brace according to claim 11, characterized in that said pressure plate (17) is stably constrained to said fabric sleeve (28) through a sewing (18'). 
Proteza za koljeno prema zahtjevu 11, naznačena time da je navedena pritisna pločica (17) stabilno ograničena na navedenom rukavu od tkanine (28) šivanjem (18).
The system according to claim 18, wherein the anaesthetic is selected from the group consisting of lignocaine (lidocaine), amethocaine (tetracaine), xylocaine, bupivacaine, prilocaine, ropivacaine, benzocaine, mepivocaine, cocaine or a mixture thereof. 
(b) je anestetik odabran iz grupe koja se sastoji od lignokaina (lidokaina), ametokaina (tetrakaina), ksilokaina, bupivakaina, prilokaina, ropivakaina, benzokaina, mepivakaina, kokaina ili njihove smjese.
The method of claim 8, wherein the anti-RSV immune response inducing composition administered to said infant is a prime or a boost. The method of claim 8, wherein the anti-RSV immune response inducing composition administered to said female was administered during the second or third trimester of pregnancy. 
Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 2, naznačen time što se pripravak koji izaziva imunosni odgovor protiv RSV kojeg se primjenjuje na navedenoj ženi primjenjuje tijekom drugog ili trećeg tromjesečja trudnoće.
R4a is a phenyl group substituted by halogen atom, a cyano group, a lower alkyl group, a halo-lower alkyl group, a lower alkoxy group, a halo-lower alkoxy group, a methylenedioxy group, an ethyleneoxy group, or a mono- or di-lower alkylamino group; or a heterocyclyl group substituted by a halogen atom, a cyano group, a lower alkyl group, or a lower alkoxy group. 
R*"* je fenilna skupina, supstituirana s atomom halogena, cijano skupinom, C;.4 alkilnom skupinom, halogen-C;. alkilnom skupinom, Cig alkoksi skupinom, halogen-C;.4 alkoksi skupinom, metilendioksi skupinom, etilenoksi skupinom ili mono- ili di-C,.4 alkilamino skupinom; ili heterociklilna skupina, supstituirana s atomom halogena, cijano skupinom, C1.4 alkilnom skupinom ili C;.4 alkoksi skupinom.
having a heavy chain comprising a polypeptide having the sequence provided in SEQ ID NO:137, and a light chain comprising a polypeptide having the sequence provided in SEQ ID NO:133; 
Protutijelo za vezanje sklerostina iz patentnog zahtjeva 1, naznačeno time, da ima teške lance SEQ ID NO: 137 i lake lance SEQ ID NO: 133.
A method for detecting a tumor, which comprises: allowing at least one of the antibody according to any one of claims 1 to 3 and the complex according to claim 4, to react with a sample collected from a living body; and detecting a signal(s) of the reacted antibody and/or antibody fragment. 
Način za detekciju tumora, koji se sastoji od: puštanja da najmanje jedno antitijelo prema bilo kojem zahtjevu od 1 do 3 i kompleks prema zahtjevu 4 reagiraju s uzorkom uzetim iz živog organizma; i detekcije signala antitijela koje je reagiralo i/ili fragmenta antitijela.
Composition according to any one of items 1 or 2, wherein the single intranasal or inhalational administration of the formulation is also capable of inducing a cytotoxic lymphocytes response. 
Upotreba pripravka prema patentnom zahtjevu 1 ili 2, naznačena time da pojedinačno intranazalno ili inhalacijsko davanje formulacije je također sposobno za induciranje citotoksičnog limfocitnog odgovora.
A light source as claimed in claim 1, wherein the plasma crucible is homogenous. 
Svjetlosni izvor u skladu s onim iz patentnog zahtjeva 1 ili 2, naznačen time, da je plazmena retorta homogena.
providing irbesartan hydrochloride having a maximum particle diameter of not more than 2000 µm, 
pribavljanje irbesartan hidroklorida čiji najveći promjer čestice nije veći od 2000 um,
The tablet of claim 1, wherein the first tablet layer composition of telmisartan is produced by spray-drying an aqueous solution comprising telmisartan and a basic agent to obtain a spray-dried granulate, mixing said spray-dried granulate with a water-soluble diluent to obtain a premix and mixing said premix with a lubricant to obtain a final blend. 
Tableta prema zahtjevu 1, naznačena time, da se sastav prvog sloja tablete od telmisartana proizvodi pomoću sprej-sušenja vodene otopine koja sadrži telmisartan i osnovnu tvar, kako bi se dobio sprejem osušeni granulat, gdje se sprejem osušeni granulat miješa s razrjeđivačem topivim u vodi, kako bi se dobila predsmjesa koja se tada miješa s lubrikantom u svrhu dobivanja konačne smjese.
The effect of compounds on the LDL oxidation induced by haemin was tested at 7 different concentrations using LDL preparations from 7 different healthy donors. 
Učinak spojeva na LDL oksidaciju izazvanu s heminom ispitan je pri 7 različitih koncentracija upotrebom LDL pripravaka iz 7 različitih zdravih donora.
The intragastric balloon (10) as claimed in any one of the preceding claims, wherein before the substances have cured the intragastric balloon (10) is adapted to be swallowed. The intragastric balloon (10) as claimed in claim 5, wherein the volume of the intragastic balloon (10) before the substances have expanded is between 1 ml and 25 ml. 
Intragastrički balon (10) sukladno bilo kojem od prethodnih patentnih zahtjeva, pri čemu se, prije no što tvari očvsnu, intragastrički balon (10) se prilagodi da proguta Intragastrički balon (10) sukladno patentom zahtjevu 5, pri čemu je obujam intragastričkog balona (10) prije no što te tvari ekspandiraju između 1 ml125 ml.
An arrangement for the recycling of carbon and hydrocarbon compounds from organic input material through pyrolysis, comprising: 
PATENTNI ZAHTJEVI Uređaj za recikliranje spojeva ugljika i ugljikovodika iz organskog ulaznog materijala putem pirolize, koji sadrži:
After its formation the first emulsion is microfluidized in order to reduce its average oil droplet size and/or to reduce the number of oil droplets having a size of >1.2 um. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time da broj uljnih kapljica koje imaju veličinu od >1.2 um nakon filtracije je 5 x 105 /ml ili manje.
An actuation handle assembly as defined in claim 11, wherein the covering element comprises an edge that laterally covers a portion of the base body, wherein the edge of the covering element is separated into two opposing areas; and 
Kontrolna ručica sukladno zahtjevu 15, naznačena time što pokrovni element (90) obuhvaća rub (92) lateralno pokrivajući bazno tijelo (41), rub pokrovnog elementa odvojen je u dva nasuprotna područja (93, 94); i
A method for the production of mixed ODVs and mixed OBs of the variant AcC6 of Autographa californica multiple nucleopolyhedrovirus (AcMNPV) and the variant SfNIC-B of Spodoptera frugiperda multiple nucleopolyhedrovirus (SfMNPV), characterized by the co-infection of both baculoviruses in Spodoptera frugiperda larvae, and subsequent insect rearing until death by polyhedrosis. 
Postupak proizvodnje miješanih ODV 1 miješanih OB varijante AcC6 višestrukog nukleopoliedrovirusa koji napada Autographa californica (AcCMNPV) i varijante STNIC-B višestrukog nukleopoliedrovirusa koji napada Spodoptera frugiperda (SEMNPV), naznačen time što se provodi suinfekciju s oba bakulovirusa kod ličinke Spodoptera frugiperda, uz naknadni uzgoj kukca do smrti od poliedroze.
A combination according to claim 8 wherein the active compound (c) is selected from the group consisting of (a) B2-agonists and (b) cortiocosteroids. 
Kombinacija u skladu s patentnim zahtjevom 5, naznačena time, da je aktivni spoj (c) odabran iz skupine koja se sastoji od (1) PDE IV inhibitora i (b) kortikosteroida.
one brewed beverage and hot water, and 
- < jedan kuhani napitak 1 vruću vodu, te
A leakage plugging device according to claim 9, wherein said at least one sealant composition resides within said condensed carrier plug or plugs to fill said at least one of a hole, a crack and breakage causing leakage at said remote site. 
Uređaj (100) za popunjavanje pukotina sukladno patentnom zahtjevu 5, naznačen time što najmanje jedan sastav brtvila ostaje unutar kondenziranog nosača (102) čepa ili čepova za ispunjavanje najmanje jednog otvora, pukotine ili loma koje uzrokuju curenja na navedenom udaljenom mjestu.
The compounds of formulae (I) and (Ia) are thus useful as vanilloid receptor antagonists, e.g., for the treatment of pain of various genesis or aetiology and as anti-inflammatory and/or anti-edemic agents for the treatment of inflammatory reactions, diseases or conditions, as well as for the treatment of allergic responses. 
Spojevi formula (1) i (Ia) se stoga, mogu upotrijebiti kao antagonisti vaniloid receptora, npr. za liječenje boli različitih genoza ili etiologije i kao antiupalna i/ili antiedemička sredstva za liječenje upalnih reakcija, bolesti ili stanja, kao također 1 za liječenje alergijskih reakcija.
Typically, the particle size of the filler(s) is in the range of 0.01-50 um, such as in the range of 0.02-25 um, and may include a nano-size filler with a particle size of maximum 100 nm. 
Tipično veličina čestica punila je u rasponu od 0.01-50 pum, kao što je raspon od 0.02-25 um, te može uključivati punila nano-veličine s veličinom čestica najviše 100 nm.
The composition for use according to any one of claims 1-13, further comprising a conditioning agent selected in the group consisting in: dimethicone or dimethyl polysiloxane, preferably linear, glycerine, almond oil (preferably Prunus amygdalus dulcis oil), phenyl trimethicone, borage oil (preferably oil from the seeds of Borago officinalis), malva extract and/or mucilage, preferably mucilage of Malva sylvetris, panthenol, extract of calendula, preferably of Calendula officinalis" ethylhexylglycerin, caprylyl glycol, aspartic acid, maltodextrins and glyceryl stearate. 
Spoj za primjenu prema bilo kojem od zahtjeva 1-13, koje dalje sadrži emulgatore iz grupe koja obuhvaća: dimetikon, ili dimetil polisiloksan, poželjno linearni, glicerin, ulje badema (poželjno uljeiz Prunus amy gdalus dulcis), fenil trimetikon, ulje boražine (poželjno ulje iz sjemena Borago officinalis), ekstrakt malve i/ili gumarabiku, poželjno gumarabiku iz vrste Malva sylvetris, pantenol, ekstrakt nevena, poželjno od Calendula officinalis, etilheksilglicerin, kaprilil glikol, asparaginsku kiselinu, maltodekstrine i gliceril stearat.
hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saccharolyticus, Clostridium difficile, Clostridium perfringens, Clostridium tetini, Clostridium botulinum, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, and Mycobacterium leprae, Chlamydia pneumoniae, Mycoplasma pneumoniae, or a combination of two or more thereof. 
hyicus, Staphylococcus haemolyticus, Staphylococcus hominis, Staphylococcus saccharolyticus, Clostridium difficile, Clostridium perfringens, Clostridium tetini, 1 Clostridium botulinum, Mycobacterium tuberculosis, Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium leprae, Chlamydia pneumoniae i Mycoplasma pneumoniae.
(IIc): wherein the stereoisomeric configuration of carbon-1 and carbon-3 of formula (II) are respectively (S, R). 
HR P20160369 T1 pri čemu je stereoizomerna konfiguracija ugljenik-1 i ugljenik-3 respektivno (5, R). 17.
A lifting device according to claim 1, wherein the handle portion extends away from the suction mount arrangement by a distance substantially equal to, or more than, the spacing between the first and second suction mount devices. 
Naprava za podizanje prema zahtjevu 1, naznačena time da se dio ručke pruža od sklopa vakuumskog nosača za udaljenost koja je potpuno jednaka, ili veća od, razmaka između prvog i drugog uređaja vakuumskog nosača.
represents an isopropyl group or a cyclopentyl group; 
R! predstavlja izopropilnu skupinu ili ciklopentilnu skupinu;
The composition for use of claim 1, wherein the polypeptide does not include amino acid residues 1-44 of SEQ ID NO: 3. 
Dvolančani polipeptid pogodan za uporabu u parenteralnoj primjeni naznačen time što sadrži aminokiselinsku sekvencu koja ima najmanje 80% homologije sa SEQ ID NO.13, pri čemu polipeptid:
According to another embodiment the liquid coating formulation used to form an absorptive layer and/or a topcoat has a solid content of 10 to 80 wt.-%, preferably of 30 to 60 wt.-%, and more preferably of 45 to 55 wt.-% based on the total weight of the formulation. 
Postupak prema zahtjevima 17 ili 18, naznačen time da tekuća formulacija premaza koji se koristi za dobivanje apsorpcijskog sloja i/ili završnog premaza koji ima sadržaj krutih tvari od 10 do 80 tež-%, poželjno od 30 do 60 tež-%, i poželjnije od 45 do 55 tež-% u odnosu na ukupnu težinu formulacije.
a compound as an active ingredient, wherein the compound is (S)-1-[(3-hydroxy-1-adamantyl)amino]acetyl-2-cyano-pyrrolidine (vildagliptin) or the corresponding amount of any of its salts; and 
(a) spoj kao aktivni sastojak, pri čemu spoj je (S)-1-[(3-hidroksi-1-adamantil)aminojacetil-2-cijano-pirolidin (vildagliptin) ili odgovarajuću količinu bilo koje od njegovih soli; te
Antibiotics such as clarithromycin and erythromycin has been used in the treatment of common pediatric infections of the middle ear and upper respiratory tract, as well as certain forms of pneumonia that affects the elderly. 
Antibiotici poput klaritromicina i eritromicina se koriste u liječenju općih pedijatrijskih infekcija srednjeg uha i gornjih dišnih puteva, kao i u liječenju određenih oblika pneumonije koja pogađa starije osobe.
Drug delivery device as described above in paragraph E, where the thermoset polyurethane comprises a polymer chain and cross-linking members, said thermoset polyurethane contains unsaturated bonds in the polymer chains and appropriate crosslinkers and/or initiators as cross-linking members. 
Uređaj za oslobađanje lijeka prema patentnom zahtjevu 16, naznačen time što termoreaktivni poliuretan sadrži polimerni lanac i unakrsno vezane članove, termoreaktivni poliuretan dalje sadrži nezasićene veze u polimernim lancima i odgovarajuće unakrsno vezana sredstva i/ili inicijatore kao unakrsno vezane članove.
To this was added diethyl acetylenedicarboxylate (1.6 mL, 10 mmol) and stirred for 1 h. 
Ovome je dodan dietil acetilendikarboksilat (1.6 mL, 10 mmol) i smjesa je miješana 1 sat.
The present invention relates to derivatives of pyrrolo[2,1-b]benzothiazepines with atypical antipsychotic activity, characterised by a good pharmacokinetic profile. 
Ovaj izum odnosi se na derivate pirolo[2,1-b]|benzotiazepina s atipičnim antipsihotičnim djelovanjem, s karakteristikom dobrog Tarmakokinetičkog profila.
A pharmaceutical composition of according to claim 1 further comprising a pharmaceutically acceptable phenolic preservative and an amount of zinc sufficient to cause the PEGylated insulin lispro compounds to hexamerize. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što dodatno sadrži farmaceutski prihvatljiv fenolni konzervans 1 količinu cinka dovoljnu za heksameriziranje PEGiliranih spojeva inzulina lispro.
The device of claim 1, wherein the actuation unit is operatively associated with the top end of the inner tube for controlling the vertical movement of the inner tube, as well as that of the first closure member, between the first position and the second position and for controlling the flow of gas through the inner tube. 
Uređaj sukladno zahtjevu 2, pri čemu je jedinica za pokretanje (62) operativno povezana s gornjim krajem unutarnje cijevi (26) za kontroliranje vertikalnog pomicanja posljednje, kao i prvog elementa za zatvaranje (36), između prvog i drugog položaja i za kontrolu protoka plina kroz unutarnju cijev (26).
A fourth type of antikine antibody has a binding specificity similar or identical to 18V4F and binds to at least two or three CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, and CCL5/RANTES. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da se veže na tri CC kemokina odabrana iz skupine koju čine CCL3/MIP-10, CCLA/MIP-1f, i CCLS/RANTES i koji se ne vežu na CCL2/MCP-I.